Steven E. Coutre
Stanford Medicine · 418 works · 34,965 citations · h-index 81
Top works
- A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
- United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia
- Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib
- Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
- Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
- International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia
- Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial
- Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia
- Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis
- Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
- Human immunodeficiency virus type 1 envelope gene structure and diversity in vivo and after cocultivation in vitro
- Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study
- PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease
- Preponderance of Thiopurine S-Methyltransferase Deficiency and Heterozygosity Among Patients Intolerant to Mercaptopurine or Azathioprine
- Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
- Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial